X

Trial Profile

A pilot study of continuous imatinib versus pulsed imatinib with or without lenograstim in chronic myeloid leukaemia patients who have achieved a complete cytogenetic response

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 14 Jun 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imatinib (Primary) ; Lenograstim
Indications Chronic myeloid leukaemia
Focus Adverse reactions
Acronyms GIMI

Most Recent Events

30 Aug 2014 New source identified and integrated (United Kingdom Clinical Research Network record: 1451)
30 Aug 2014 According to the United Kingdom Clinical Research Network record, accrual to Date is 100%
19 May 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com